CARsgen Therapeutics Holdings Ltd (HKG: 2171), based in China, has announced that it has received clinical trial approval from the U.S. FDA for its chimeric antigen receptor (CAR)-T cell product, CT071, aimed at treating recurrent/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (PCL).
CT071 is developed using the CARcelerate platform and specifically targets G-protein coupled receptor family C group 5 member D (GPRC5D), which is significantly overexpressed on malignant plasma cells, making it a compelling target for MM and PCL therapies. The product is currently undergoing investigator-initiated trials (ITT) in China to evaluate its safety and efficacy in R/R MM and PCL.- Flcube.com
